advanced search

Welcome: Guest

log in

The Pharmaceutical Market: Belgium

Publication Date October 2008
Publisher Espicom
Product Type Report
Pages 100
ISBN Number not applicable
Product Code ESP00221
Buy this product or for assistance call +44 20 7060 7474

Summary

Pharmaceutical consumption in Belgium is comparatively high, although the complicated reimbursement system has hindered access to innovative drugs in the past. More recently, the government has attempted to speed up regulatory procedures and improve access to new drugs of major therapeutic value. However, the market is only showing modest growth as the move towards more costly innovative medicines is counterbalanced by downward pressure on prices for more mature products. Fears that Belgium's pharmaceutical sector was starting to lose out competitively to other European countries has resulted in the setting up of a federal drugs agency, which officially started operations in 2007.

The market is divided into two linguistic regions; the northern Dutch speaking region of Flanders and the southern French speaking region of Wallonia. The capital, Brussels, is situated in the Dutch region but has bilingual status. Most pharmaceutical companies active in the Belgian market operate through their own Belgian-based subsidiaries, while a few use the services of indigenous manufacturers.

The Belgian healthcare system is based on the principles of equitable access and freedom of choice. The majority of healthcare providers are independent practitioners who are paid on a fee-for-service basis. Management of the healthcare system in Belgium is complicated by the country's system of multiple governments at federal, regional and community level. Political wrangling between the Flemish and Walloon political groups over how much power should be devolved from the federal government to the regions was the main reason for the nine-month delay in forming a new government following legislative elections in June 2007.

in 2008, GDP is forecast to rise to US$536.2 billion, but this is largely due to the effects of the weak dollar. Real GDP growth is expected to be around 1.4% in 2008, falling to 1.2% in 2009.

Content

  • 1. Executive Summary
  • 2. Introduction
  • 3. Current market size
  • 4. Market structure
  • 5. Generic usage
  • 6. OTC market
  • 7. Market projections & outlook
  • 8. Imports
  • 9. Domestic manufacturing
  • 10. Multinational manufacturing
  • 11. Exports
  • 12. Research & development
  • 13. Pharmaceutical regulations
  • 14. Pricing & reimbursement
  • 15. Intellectual property
  • 16. Distribution & retail
  • 17. Demographics
  • 18. Healthcare system
  • 19. Health expenditure
  • 20. Healthcare infrastructure
  • 21. Healthcare personnel
  • 22. Directory
  • 23. Methodology & sources
  • 97. Appendix: healthcare statistics
Delivery Details

PDF:Delivered by email usually within 4 to 8 UK business hours.

PRINT/CD-ROM:Despatched within 1 to 2 working days.

Industry Events

2nd International Conference on Drug Discovery and Therapy

01 Feb 10 to 04 Feb 10
Dubai, United Arab Emirates
view summary >>

Proteins Congress

29 Oct 09 to 30 Oct 09
Berlin, Germany
view summary >>

#